Jefferies analyst Akash Tewari raised the firm’s price target on Argenx to $497 from $465 and keeps a Buy rating on the shares. The company’s efgartigimod Phase 2 in LC-POTS is an under-the-radar catalyst, and the firm believes there is reasonable clinical rationale with a number of cases providing early PoC, the analyst tells investors in a research note. Jefferies thinks Long COVID-POTS represents a significant market opportunity.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARGX:
- Argenx congenital myasthenic syndrome treatment granted orphan designation
- Argenx price target raised to $465 from $455 at Jefferies
- Halozyme says Argenx receives FDA approval for Vyvgart Hytrulo with Enhanze
- argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis
- Argenx announces FDA approval of VYVGART Hytrulo
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue